CureApp’s digital therapeutic solution for hypertension receives insurance coverage

KUALA LUMPUR, Nov 3 (Bernama) -- CureApp Inc has announced the start of insurance coverage for its CureApp HT Hypertension Adjunctive Treatment App (CureApp HT), a digital therapeutics (DTx) solution treating hypertension, in Japan from Sept 1, 2022.

This marks the first case of a DTx treatment solution being covered by insurance in the field of hypertension in the world.

In a statement, the company said looking ahead, the app would be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.

It said after confirming the efficacy and safety of CureApp HT through clinical trials, the results of a Japanese Phase III domestic multicenter randomised controlled trial were published in EHJ, one of the most well-respected peer-reviewed journals in the world in 2021.

In April 2022, CureApp HT was the first digital therapeutics app for hypertension to receive government approval worldwide.

CureApp HT helps connect doctors and patients and promotes lifestyle changes that were previously difficult to maintain while ensuring sustained modified behaviour in patients.

CureApp looks to pursue further commercialisation efforts of this Japanese-led medical innovation and plans to proactively expand CureApp HT’s reach all over the world, beginning with the United States.

-- BERNAMA